Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 2/2011

01-04-2011 | Review Article

Proteomic analysis of soft tissue sarcoma

Author: Yoshiyuki Suehara

Published in: International Journal of Clinical Oncology | Issue 2/2011

Login to get access

Abstract

Soft tissue sarcomas are a heterogeneous group of malignant mesenchymal tumors, and novel tumors biomarkers and therapeutic targets are required to achieve early diagnosis and optimize therapy for individual patients. Global protein expression studies, an approach known as “proteomics”, can offer important clues for understanding tumor biology that cannot be obtained by other approaches. Proteomic studies, such as two-dimensional difference gel electrophoresis (2D-DIGE) and mass spectrometry, have provided protein expression profiles of soft tissue tumors that can be used to develop novel diagnostic and therapeutic biomarkers and allow molecular classification of tumors. In this article, a brief description of the methodology will be provided, followed by a few examples of the recent proteomic studies that have generated new information for the diagnosis, classification and treatment of soft tissue tumors.
Literature
1.
Fletcher CDM, Unni KK, Mertens F (2002) World health organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone. IARC Press, Lyon
2.
Tschoep K, Kohlmann A, Schlemmer M et al (2007) Gene expression profiling in sarcomas. Crit Rev Oncol Hematol 63:111–124PubMedCrossRef
3.
Francis P, Namlos HM, Muller C et al (2007) Diagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potential. BMC Genomics 8:73PubMedCrossRef
4.
Allander SV, Illei PB, Chen Y et al (2002) Expression profiling of synovial sarcoma by cDNA microarrays: association of ERBB2, IGFBP2, and ELF3 with epithelial differentiation. Am J Pathol 161:1587–1595PubMedCrossRef
5.
Nakagawa Y, Numoto K, Yoshida A et al (2006) Chromosomal and genetic imbalances in synovial sarcoma detected by conventional and microarray comparative genomic hybridization. J Cancer Res Clin Oncol 132:444–450PubMedCrossRef
6.
Lee YF, John M, Falconer A et al (2004) A gene expression signature associated with metastatic outcome in human leiomyosarcomas. Cancer Res 64:7201–7204PubMedCrossRef
7.
Nielsen TO, West RB, Linn SC et al (2002) Molecular characterisation of soft tissue tumours: a gene expression study. Lancet 359:1301–1307PubMedCrossRef
8.
Nagayama S, Katagiri T, Tsunoda T et al (2002) Genome-wide analysis of gene expression in synovial sarcomas using a cDNA microarray. Cancer Res 62:5859–5866PubMed
9.
Nakayama R, Mitani S, Nakagawa T et al (2010) Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am J Surg Pathol 34:1599–1607PubMed
10.
Antonescu CR (2008) Molecular profiling in the diagnosis and treatment of high grade sarcomas. Ultrastruct Pathol 32:37–42PubMedCrossRef
11.
Kawai A, Kondo T, Suehara Y et al (2008) Global protein-expression analysis of bone and soft tissue sarcomas. Clin Orthop Relat Res 466:2099–2106PubMedCrossRef
12.
13.
Suehara Y, Kondo T, Fujii K et al (2006) Proteomic signatures corresponding to histological classification and grading of soft-tissue sarcomas. Proteomics 6:4402–4409PubMedCrossRef
14.
Gygi SP, Rochon Y, Franza BR et al (1999) Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19:1720–1730PubMed
15.
Chen G, Gharib TG, Huang CC et al (2002) Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 1:304–313PubMedCrossRef
16.
Yanagisawa K, Shyr Y, Xu BJ et al (2003) Proteomic patterns of tumour subsets in non-small-cell lung cancer. Lancet 362:433–439PubMedCrossRef
17.
Alaiya AA, Franzen B, Hagman A et al (2002) Molecular classification of borderline ovarian tumors using hierarchical cluster analysis of protein expression profiles. Int J Cancer 98:895–899PubMedCrossRef
18.
Reyzer ML, Caldwell RL, Dugger TC et al (2004) Early changes in protein expression detected by mass spectrometry predict tumor response to molecular therapeutics. Cancer Res 64:9093–9100PubMedCrossRef
19.
Cui JW, Wang J, He K et al (2004) Proteomic analysis of human acute leukemia cells: insight into their classification. Clin Cancer Res 10:6887–6896PubMedCrossRef
20.
Varambally S, Yu J, Laxman B et al (2005) Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 8:393–406PubMedCrossRef
21.
Suehara Y, Kikuta K, Nakayama R et al (2010) GST-P1 as a histological biomarker of synovial sarcoma revealed by proteomics. Proteomics Clin Appl 3:623–634CrossRef
22.
Suehara Y, Kikuta K, Nakayama R et al (2010) Anatomic site-specific proteomic signatures of gastrointestinal stromal tumors. Proteomics Clin Appl 3:584–596CrossRef
23.
Takahashi T, Naka T, Fujimoto M et al (2008) Aberrant expression of glycosylation in juvenile gastrointestinal stromal tumors. Proteomics Clin Appl 2:1246–1254PubMedCrossRef
24.
Li Y, Liang Q, Wen YQ et al (2010) Comparative proteomics analysis of human osteosarcomas and benign tumor of bone. Cancer Genet Cytogenet 198:97–106PubMedCrossRef
25.
Li Y, Dang TA, Shen J et al (2006) Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics 6:3426–3435PubMedCrossRef
26.
Fetsch PA, Simone NL, Bryant-Greenwood PK et al (2002) Proteomic evaluation of archival cytologic material using SELDI affinity mass spectrometry: potential for diagnostic applications. Am J Clin Pathol 118:870–876PubMedCrossRef
27.
Kikuta K, Tochigi N, Shimoda T et al (2009) Nucleophosmin as a candidate prognostic biomarker of Ewing’s sarcoma revealed by proteomics. Clin Cancer Res 15:2885–2894PubMedCrossRef
28.
Suehara Y, Kondo T, Seki K et al (2008) Pfetin as a prognostic biomarker of gastrointestinal stromal tumors revealed by proteomics. Clin Cancer Res 14:1707–1717PubMedCrossRef
29.
Holt GE, Schwartz HS, Caldwell RL (2006) Proteomic profiling in musculoskeletal oncology by MALDI mass spectrometry. Clin Orthop Relat Res 450:105–110PubMedCrossRef
30.
Suehara Y, Tochigi N, Kubota D et al (2011) Secernin-1 as a novel prognostic biomarker candidate of synovial sarcoma revealed by proteomics. J Proteomics (in press)
31.
Kang HJ, Koh KH, Yang E et al (2006) Differentially expressed proteins in gastrointestinal stromal tumors with KIT and PDGFRA mutations. Proteomics 6:1151–1157PubMedCrossRef
32.
Kikuta K, Tochigi N, Saito S et al (2010) Peroxiredoxin 2 as a chemotherapy responsiveness biomarker candidate in osteosarcoma revealed by proteomics. Proteomics Clin Appl 4:560–567PubMed
33.
Conrad DH, Goyette J, Thomas PS (2008) Proteomics as a method for early detection of cancer: a review of proteomics, exhaled breath condensate, and lung cancer screening. J Gen Intern Med 23(Suppl 1):78–84PubMedCrossRef
34.
Alessandro R, Fontana S, Kohn E et al (2005) Proteomic strategies and their application in cancer research. Tumori 91:447–455PubMed
35.
Granville CA, Dennis PA (2005) An overview of lung cancer genomics and proteomics. Am J Respir Cell Mol Biol 32:169–176PubMedCrossRef
36.
Kondo T, Hirohashi S (2006) Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc 1:2940–2956PubMedCrossRef
37.
Kondo T, Hirohashi S (2009) Application of 2D-DIGE in cancer proteomics toward personalized medicine. Methods Mol Biol 577:135–154PubMedCrossRef
38.
Nakayama R, Nemoto T, Takahashi H et al (2007) Gene expression analysis of soft tissue sarcomas: characterization and reclassification of malignant fibrous histiocytoma. Mod Pathol 20:749–759PubMedCrossRef
39.
Suda T, Tsunoda T, Uchida N et al (2006) Identification of secernin 1 as a novel immunotherapy target for gastric cancer using the expression profiles of cDNA microarray. Cancer Sci 97:411–419PubMedCrossRef
40.
Ueda T, Aozasa K, Tsujimoto M et al (1988) Prognostic significance of mast cells in soft tissue sarcoma. Cancer 62:2416–2419PubMedCrossRef
41.
Oda Y, Hashimoto H, Tsuneyoshi M et al (1993) Survival in synovial sarcoma. A multivariate study of prognostic factors with special emphasis on the comparison between early death and long-term survival. Am J Surg Pathol 17:35–44PubMedCrossRef
42.
Joensuu H, Roberts PJ, Sarlomo-Rikala M et al (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344:1052–1056PubMedCrossRef
43.
van der Zwan SM, DeMatteo RP (2005) Gastrointestinal stromal tumor: 5 years later. Cancer 104:1781–1788PubMedCrossRef
44.
Kang HJ, Nam SW, Kim H et al (2005) Correlation of KIT and platelet-derived growth factor receptor alpha mutations with gene activation and expression profiles in gastrointestinal stromal tumors. Oncogene 24:1066–1074PubMedCrossRef
45.
Antonescu CR, Viale A, Sarran L et al (2004) Gene expression in gastrointestinal stromal tumors is distinguished by KIT genotype and anatomic site. Clin Cancer Res 10:3282–3290PubMedCrossRef
46.
El-Rifai W, Sarlomo-Rikala M, Andersson LC et al (2000) DNA sequence copy number changes in gastrointestinal stromal tumors: tumor progression and prognostic significance. Cancer Res 60:3899–3903PubMed
47.
Pruneri G, Mazzarol G, Fabris S et al (2003) Cyclin D3 immunoreactivity in gastrointestinal stromal tumors is independent of cyclin D3 gene amplification and is associated with nuclear p27 accumulation. Mod Pathol 16:886–892PubMedCrossRef
48.
Koon N, Schneider-Stock R, Sarlomo-Rikala M et al (2004) Molecular targets for tumour progression in gastrointestinal stromal tumours. Gut 53:235–240PubMedCrossRef
49.
Kikuta K, Gotoh M, Kanda T et al (2009) Pfetin as a prognostic biomarker in gastrointestinal stromal tumor: novel monoclonal antibody and external validation study in multiple clinical facilities. Jpn J Clin Oncol 40:60–72
50.
Blanke CD, Demetri GD, von Mehren M et al (2008) Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26:620–625PubMedCrossRef
51.
Blanke CD, Rankin C, Demetri GD et al (2008) Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626–632PubMedCrossRef
52.
Verweij J, Casali PG, Zalcberg J et al (2004) Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364:1127–1134PubMedCrossRef
53.
Resendes BL, Kuo SF, Robertson NG et al (2004) Isolation from cochlea of a novel human intronless gene with predominant fetal expression. J Assoc Res Otolaryngol 5:185–202PubMed
Metadata
Title
Proteomic analysis of soft tissue sarcoma
Author
Yoshiyuki Suehara
Publication date
01-04-2011
Publisher
Springer Japan
Published in
International Journal of Clinical Oncology / Issue 2/2011
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-011-0203-9

Other articles of this Issue 2/2011

International Journal of Clinical Oncology 2/2011 Go to the issue

Case Report

An inconspicuous fallopian-tube carcinoma clinically manifested as a rectovaginal septal tumor: a pitfall for diagnosis and treatment

Review Article

Cryoimmunology for malignant bone and soft-tissue tumors

Original Article

Hepatic resection with or without adjuvant iodine-131-lipiodol for hepatocellular carcinoma: a comparative analysis

Review Article

Tumor imaging with multicolor fluorescent protein expression

Original Article

Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy

Editorial Announcement

Announcing our new journal: International Cancer Conference Journal (ICCJ)
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits